Biorestorative Therapies
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Introduction
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- BioRestorative Therapies
- Target Recruit Count
- 99
- Registration Number
- NCT04042844
- Locations
- 🇺🇸
Source Healthcare, Santa Monica, California, United States
🇺🇸Boomerang Healthcare, Walnut Creek, California, United States
🇺🇸Coastal Health, Jacksonville, Florida, United States
News
BioRestorative Therapies Secures Japanese Patent for ThermoStem® Cell-Based Obesity Treatment Platform
BioRestorative Therapies received a Notice of Allowance from the Japanese Patent Office for its ThermoStem® platform, providing broad protection for brown adipose-derived stem cell technology targeting obesity and metabolic disorders.
BioRestorative Therapies Reports Strong Financial Growth and Clinical Advancements in 2024
BioRestorative Therapies reported a 175% revenue increase to $401,000 in 2024, with a 24% improvement in operating loss and a strong cash position of $10.7 million with no outstanding debt.
FDA Grants Fast Track Status to BRTX-100 for Chronic Lumbar Disc Disease Treatment
BioRestorative Therapies receives FDA Fast Track designation for BRTX-100, accelerating the development pathway for their chronic lumbar disc disease treatment program.
BioRestorative Therapies' BRTX-100 Shows Positive Phase 2 Data for Chronic Lumbar Disc Disease
BioRestorative Therapies reports positive preliminary data from its Phase 2 trial of BRTX-100 for chronic lumbar disc disease (cLDD).